Drug Trial Radar · NCT05702450
Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Mar 22, 2023
Primary completion
Jul 26, 2023
Study completion Jul 26, 2023
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.
Conditions
- Healthy
Interventions
CM310Biological
CM310 Recombinant Humanized Monoclonal Antibody Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic: the maximum concentration (Cmax)Time frame: up to 57 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PKUCare Luzhong Hospital
Zibo, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.